Role of quinolones and quinoxaline derivatives in the advancement of treatment of tuberculosis

Asif, Mohammad

doi:10.14419/ijsw.v3i1.3432

Cited by 7 publications

(3 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These inhibitors can interact with DprE1 through covalent or noncovalent interactions. Noncovalent inhibitors include benzothiazinone (PyrBTZ01), 45 thiophene (TCA1), 46 quinoxaline, 47 dinitrobenzamide, thiadiazoles, azaindole, pyrazole pyridine, aminoquinolines, and piperidine amides. Covalent inhibitors include nitrobenzothiazoinone (BTZ), benzothiazole, triazole, and nitrobenzamide 48 (Figure 2).…”

Section: Potential Targetsmentioning

confidence: 99%

Revolutionizing Tuberculosis Treatment: Uncovering New Drugs and Breakthrough Inhibitors to Combat Drug-Resistant Mycobacterium tuberculosis

Verma,

Naik,

Kumar

et al. 2023

ACS Infect. Dis.

View full text Add to dashboard Cite

Tuberculosis (TB) is a global health threat that causes significant mortality. This review explores chemotherapeutics that target essential processes in Mycobacterium tuberculosis, such as DNA replication, protein synthesis, cell wall formation, energy metabolism, and proteolysis. We emphasize the need for new drugs to treat drug-resistant strains and shorten the treatment duration. Emerging targets and promising inhibitors were identified by examining the intricate biology of TB. This review provides an overview of recent developments in the search for anti-TB drugs with a focus on newly validated targets and inhibitors. We aimed to contribute to efforts to combat TB and improve therapeutic outcomes.

show abstract

Section: Potential Targetsmentioning

confidence: 99%

Revolutionizing Tuberculosis Treatment: Uncovering New Drugs and Breakthrough Inhibitors to Combat Drug-Resistant Mycobacterium tuberculosis

Verma,

Naik,

Kumar

et al. 2023

ACS Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…The antibacterial activity of quinolones versus a variety of Gram-negative/positive bacteria has been reported by many researchers [ 58 , 59 ]. Fluoroquinolones (Fig.…”

Section: Therapeutic Applications Of Quinolone Containing Compoundsmentioning

confidence: 99%

Quinolone: a versatile therapeutic compound class

2022

View full text Add to dashboard Cite

The discovery of nalidixic acid is one pinnacle in medicinal chemistry, which opened a new area of research that has led to the discovery of several life-saving antimicrobial agents (generally referred to as fluoroquinolones) for over decades. Although fluoroquinolones are frequently encountered in the literature, the utility of quinolone compounds extends far beyond the applications of fluoroquinolones. Quinolone-based compounds have been reported for activity against malaria, tuberculosis, fungal and helminth infections, etc. Hence, the quinolone scaffold is of great interest to several researchers in diverse disciplines. This article highlights the versatility of the quinolone pharmacophore as a therapeutic agent beyond the fluoroquinolone profile. Graphical abstract

show abstract

“…LVX is frequently prescribed to treat E. coli infections ( 14 , 20 – 22 ). Because LVX is an effective therapeutic agent, it is prescribed by Iranian physicians for treating infections.…”

Section: Introductionmentioning

confidence: 99%

Resistance pattern of Escherichia coli to levofloxacin in Iran, a narrative review

Hassanshahi¹,

Darehkordi²,

Fathollahi³

et al. 2020

IJM

View full text Add to dashboard Cite

Fluoroquinolones (FQs) are widely used in the treatment of infections caused by Escherichia coli. FQs are broad spectrum antibiotics with high tissue penetration, and ease of use. Therefore, given the concerns existing about drug resistance, we aim to review the latest findings about resistance patterns to levofloxacin (LVX) along with other FQs in E. coli infections in different parts of Iran. Evidence shows that quinolones have been used in Iran for nearly 50 years, and that 0-65% of E. coli isolates show resistance to FQs. In the western parts of Iran, the highest rate of resistance to LVX (66.7%) has been reported among patients having urinary tract infections with E. coli isolates. Few studies and information exist on the antimicrobial re- sistance of E. coli to LVX in different geographical locations of Iran. However, the findings of various studies on this subject show that E. coli resistance to LVX is more in the western part of Iran than in central and southern regions, but it is similar among inpatients and outpatients. Therefore, it is reasonable advisable to limit the overuse, inappropriate prescription, and self-medication of LVX to prevent the induction of FQ-resistant strains. Accordingly, in order to obtain a clearer image of resistance to FQs, especially LVX in E. coli in Iran, more extensive investigations in different geographical locations and periods of time are required. In addition, antimicrobial stewardship would be helpful in this regard.

show abstract

Role of quinolones and quinoxaline derivatives in the advancement of treatment of tuberculosis

Cited by 7 publications

References 148 publications

Revolutionizing Tuberculosis Treatment: Uncovering New Drugs and Breakthrough Inhibitors to Combat Drug-Resistant Mycobacterium tuberculosis

Revolutionizing Tuberculosis Treatment: Uncovering New Drugs and Breakthrough Inhibitors to Combat Drug-Resistant Mycobacterium tuberculosis

Quinolone: a versatile therapeutic compound class

Resistance pattern of Escherichia coli to levofloxacin in Iran, a narrative review

Contact Info

Product

Resources

About